ORLANDO, FL—(UPDATED) Through 5 years, TAVI with a self-expanding valve provided clinical outcomes similar to those seen with surgery in an intermediate-risk population, according to continued ...

COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Thubrikar Aortic Valve, Inc. today announced successful results in an additional 5 patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) ...

Transcatheter aortic valve implantation (TAVI) has been touted for “revolutionizing the field of cardiology,” as the preferred treatment for most patients over age 70 years with severe aortic stenosis ...

Valve-in-valve (ViV) transcatheter procedures for a failed aortic bioprosthesis are associated with a lower risk of in-hospital mortality compared with a repeat surgical aortic valve replacement, but ...

The CE Mark pivotal study is ongoing, and 120 patients are planned to be enrolled. In Barcelona, Treede reported on the first 61 patients to receive the valve, although one did not receive the Engager ...

SAN DIEGO — A self-expanding valve was equivalent to a balloon-expandable valve for 30-day outcomes in patients with symptomatic aortic stenosis who underwent transfemoral transcatheter aortic valve ...

NORRISTOWN, Pa.--(BUSINESS WIRE)--Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in ...

Advances in our understanding of the mechanisms underlying valvular heart diseases, together with technological innovations and accumulating clinical experience, have led to great improvements in the ...